For any clinical candidate, the Target Product Profile (TPP) serves as the blueprint for its commercial future. However, many profiles are hampered by fragmented, generic, or historical data that fails to reflect today’s market reality. Omnitheia optimizes the TPP by infusing it with Real-World Evidence (RWE) to validate both its clinical and commercial potential.
Building a TPP with Evidence-Backed Authority
We utilize over 100,000 curated data sources and direct stakeholder insights to build a TPP that is not just competitive, but fully backed by real-world evidence of its clinical and commercial potential. This methodology is applicable to any clinical candidate, ensuring that every asset in your pipeline is positioned with maximum authority.
- Curated Data Integration: We cross-reference internal clinical benchmarks against live market data to identify an asset’s “Data Edge”—such as proprietary biomarker-driven efficacy.
- Stakeholder-Validated Positioning: We refine the TPP using direct insights from the frontline of medicine:
- KOLs & HCPs: Confirming the specific efficacy and safety thresholds required to displace current standards of care.
- Payors: Identifying the specific evidence needed to justify a premium price point and ensure long-term reimbursement potential.
Strategic Asset Positioning
By moving away from fragmented datasets toward a unified, evidence-backed profile, Omnitheia ensures that an asset’s positioning is grounded in commercial reality. This enables Licensing Directors and pipeline leaders to structure term sheets and valuations based on the true market demand and the clinical necessity of their drug candidate.
